文献速递浆细胞疾病

伊沙妥昔单抗、卡非佐米、来那度胺和地塞米松诱导治疗新诊断多发性骨髓瘤:MIDAS 试验分析

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial.
PubMed 文献 · Blood · 2025-01-01

MIDAS 研究评估适合移植的新诊断多发性骨髓瘤患者接受 IsaKRD 诱导 6 个周期(28 天/周期)的安全性和疗效,共 791 例,中位年龄 59 岁。诱导后 91% 达非常好的部分缓解及以上,10⁻⁵ 和 10⁻⁶ 灵敏度下 MRD 阴性率分别为 63% 和 47%,无新安全性信号;需继续随访确认。

要点

  • IsaKRD 诱导 6 周期后 91% 患者达非常好的部分缓解及以上,10⁻⁵ MRD 阴性率 63%、10⁻⁶ 为 47%。
  • 3/4 级不良事件最常见为中性粒细胞减少 25%、血小板减少 5%、感染 7%;任何级别周围神经病变仅 13%。
  • 96% 患者完成诱导,中位 CD34+ 细胞采集量 7×10⁶/kg,94% 可进行潜在串联移植。

核心结论

  • IsaKRD 诱导产生深度缓解和高 MRD 阴性率,同时确保干细胞采集成功,无新安全性信号;需继续随访确认。

研究设计与样本

  • 3 期 IFM2020-02-MRD-adapted strategy(MIDAS)研究,报告 791 例适合移植新诊断多发性骨髓瘤患者接受 6 个 28 天周期 IsaKRD 诱导的安全性和疗效。

主要发现

  • 中位年龄 59 岁;ISS III 期 13%,修订 ISS III 期 5%,高危细胞遗传学(IMeL 线性预测细胞遗传学评分 >1)8%。
  • 96%(N=757)患者完成诱导;中位 CD34+ 细胞采集量 7×10⁶/kg,94% 患者可进行潜在串联移植。
  • 最佳总缓解率 95%;意向治疗人群中 91% 诱导后达非常好的部分缓解及以上,10⁻⁵ 和 10⁻⁶ 灵敏度下 MRD 阴性率分别为 63% 和 47%。
  • 诱导期间 7 例疾病进展,5 例死亡(疾病进展 n=1、心脏事件 n=2、其他原因 n=2)。
  • 最常见 3/4 级不良事件为中性粒细胞减少 25%、血小板减少 5%、感染 7%;任何级别周围神经病变仅 13%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需继续随访这项正在进行的研究以确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For patients with transplant-eligible newly diagnosed multiple myeloma, induction therapy with a quadruplet regimen before autologous transplant is the standard of care. The phase 3 IFM2020-02-MRD-adapted strategy (MIDAS) study assessed a minimal residual disease (MRD)-driven consolidation and maintenance strategy after induction with isatuximab, carfilzomib, lenalidomide, and dexamethasone (IsaKRD). We report safety and efficacy outcomes of six 28-day cycles of IsaKRD in 791 patients. The median age was 59 years; 13% had International Staging System (ISS) stage III, 5% Revised-ISS stage III, and 8% high-risk cytogenetics (Intergroupe Francophone du Myélome linear predictor cytogenetic score of >1). Overall, 96% (N = 757) of patients completed induction. The median CD34+ cell yield was 7 × 106/kg, with 94% of patients able to proceed with a potential tandem transplant. The best overall response rate was 95%. In the intent-to-treat population, 91% achieved a very good partial response or better after induction, with MRD-negativity rates of 63% at 10-5 and 47% at 10-6. During induction, 7 patients experienced disease progression, and 5 died due to disease progression (n = 1), cardiac events (n = 2), or other causes (n = 2). The most common grade 3/4 adverse events were neutropenia (25%), thrombocytopenia (5%), and infections (7%); only 13% of patients reported any grade peripheral neuropathy. IsaKRD induction yielded deep responses and high MRD-negativity rates while ensuring successful stem cell collection, with no new safety signals. Continued follow-up of this ongoing study is required to confirm these findings. This trial was registered at www.clinicaltrials.gov as #NCT04934475.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Perrot A, Touzeau C, Lambert J, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial. Blood. 2025. PMID: 39841461. doi:10.1182/blood.2024026230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。